Niclosamide Suppresses Migration and Invasion of Human Osteosarcoma Cells by Repressing TGFBI Expression Via the ERK Signaling Pathway

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jan 11

PMID 35008910

Authors

Liang-Tsai Yeh

Chiao-Wen Lin

Ko-Hsiu Lu

Yi-Hsien Hsieh

Chao-Bin Yeh

Shun-Fa Yang

Jia-Sin Yang

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma is a highly common malignant bone tumor. Its highly metastatic properties are the leading cause of mortality for cancer. Niclosamide, a salicylanilide derivative, is an oral antihelminthic drug of known anticancer potential. However, the effect of niclosamide on osteosarcoma cell migration, invasion and the mechanisms underlying have not been fully clarified. Therefore, this study investigated niclosamide's underlying pathways and antimetastatic effects on osteosarcoma. In this study, U2OS and HOS osteosarcoma cell lines were treated with niclosamide and then subjected to assays for determining cell migration ability. The results indicated that niclosamide, at concentrations of up to 200 nM, inhibited the migration and invasion of human osteosarcoma U2OS and HOS cells and repressed the transforming growth factor beta-induced protein (TGFBI) expression of U2OS cells, without cytotoxicity. After TGFBI knockdown occurred, cellular migration and invasion behaviors of U2OS cells were significantly reduced. Moreover, niclosamide significantly decreased the phosphorylation of ERK1/2 in U2OS cells and the combination treatment of the MEK inhibitor (U0126) and niclosamide resulted in the intensive inhibition of the TGFBI expression and the migratory ability in U2OS cells. Therefore, TGFBI derived from osteosarcoma cells via the ERK pathway contributed to cellular migration and invasion and niclosamide inhibited these processes. These findings indicate that niclosamide may be a powerful preventive agent against the development and metastasis of osteosarcoma.

Citing Articles

Global research trends and hotspots in metabolomics of osteosarcoma: a decade-spanning bibliometric and visualized analysis.

Tu J, Liu T, Li J, Long J, Wang X, Liu W Front Immunol. 2024; 15:1463078.

PMID: 39445018 PMC: 11496093. DOI: 10.3389/fimmu.2024.1463078.

Targeting nerve growth factor-mediated osteosarcoma metastasis: mechanistic insights and therapeutic opportunities using larotrectinib.

Hou C, Chen W, Lin C Cell Death Dis. 2024; 15(5):381.

PMID: 38816365 PMC: 11139949. DOI: 10.1038/s41419-024-06752-0.

DOCK1 regulates the malignant biological behavior of endometrial cancer through c-Raf/ERK pathway.

Xie S, Jin Y, Wang J, Li J, Peng M, Zhu X BMC Cancer. 2024; 24(1):296.

PMID: 38438882 PMC: 10913561. DOI: 10.1186/s12885-024-12030-1.

Repurposable Drugs for Immunotherapy and Strategies to Find Candidate Drugs.

Sakai N, Kamimura K, Terai S Pharmaceutics. 2023; 15(9).

PMID: 37765160 PMC: 10536625. DOI: 10.3390/pharmaceutics15092190.

Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging.

Suranova M, duris M, Stenglova Netikova I, Brabek J, Horak T, Juzova V Biomed Opt Express. 2023; 14(6):2689-2708.

PMID: 37342686 PMC: 10278600. DOI: 10.1364/BOE.488630.

References

Tao H, Zhang Y, Zeng X, Shulman G, Jin S . Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. Nat Med. 2014; 20(11):1263-9. PMC: 4299950. DOI: 10.1038/nm.3699. View

Li Z, Li X, Xu D, Chen X, Li S, Zhang L . An update on the roles of circular RNAs in osteosarcoma. Cell Prolif. 2020; 54(1):e12936. PMC: 7791175. DOI: 10.1111/cpr.12936. View

Kadri H, Lambourne O, Mehellou Y . Niclosamide, a Drug with Many (Re)purposes. ChemMedChem. 2018; 13(11):1088-1091. PMC: 7162286. DOI: 10.1002/cmdc.201800100. View

Sugiura R, Satoh R, Takasaki T . ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer. Cells. 2021; 10(10). PMC: 8533760. DOI: 10.3390/cells10102509. View

Wen G, Hong M, Li B, Liao W, Cheng S, Hu B . Transforming growth factor-β-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway. Int J Oncol. 2011; 39(4):1001-9. PMC: 4090925. DOI: 10.3892/ijo.2011.1097. View

Lu K, Lu E, Lin C, Yang J, Yang S . New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma. Pharmacol Ther. 2020; 214:107611. DOI: 10.1016/j.pharmthera.2020.107611. View

Suliman M, Zhang Z, Na H, Ribeiro A, Zhang Y, Niang B . Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family. Int J Mol Med. 2016; 38(3):776-84. PMC: 4990307. DOI: 10.3892/ijmm.2016.2689. View

Al-Hadiya B . Niclosamide: comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2012; 32:67-96. DOI: 10.1016/S0099-5428(05)32002-8. View

Satoh K, Zhang L, Zhang Y, Chelluri R, Boufraqech M, Nilubol N . Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016; 22(14):3458-66. PMC: 4947455. DOI: 10.1158/1078-0432.CCR-15-2256. View

10.

Chen W, Mook Jr R, Premont R, Wang J . Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2017; 41:89-96. PMC: 5628105. DOI: 10.1016/j.cellsig.2017.04.001. View

11.

Li X, Ding R, Han Z, Ma Z, Wang Y . Targeting of cell cycle and let-7a/STAT3 pathway by niclosamide inhibits proliferation, migration and invasion in oral squamous cell carcinoma cells. Biomed Pharmacother. 2017; 96:434-442. DOI: 10.1016/j.biopha.2017.09.149. View

12.

Liu J, Chen P, Chang T, Hou C . Monocyte Chemoattractant Protein-1 promotes cancer cell migration via c-Raf/MAPK/AP-1 pathway and MMP-9 production in osteosarcoma. J Exp Clin Cancer Res. 2020; 39(1):254. PMC: 7684958. DOI: 10.1186/s13046-020-01756-y. View

13.

Lu K, Lin C, Hsieh Y, Su S, Reiter R, Yang S . New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence. Cancer Metastasis Rev. 2020; 39(1):303-320. DOI: 10.1007/s10555-020-09845-2. View

14.

McCubrey J, Steelman L, Chappell W, Abrams S, Wong E, Chang F . Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2006; 1773(8):1263-84. PMC: 2696318. DOI: 10.1016/j.bbamcr.2006.10.001. View

15.

Lee S, Kim J, Kim H, Schlaepfer D, Kim I, Nam J . Endothelial angiogenic activity and adipose angiogenesis is controlled by extracellular matrix protein TGFBI. Sci Rep. 2021; 11(1):9644. PMC: 8102489. DOI: 10.1038/s41598-021-88959-1. View

16.

Li Z, Yu Y, Sun S, Qi B, Wang W, Yu A . Niclosamide inhibits the proliferation of human osteosarcoma cell lines by inducing apoptosis and cell cycle arrest. Oncol Rep. 2015; 33(4):1763-8. DOI: 10.3892/or.2015.3766. View

17.

Cheng B, Morales L, Zhang Y, Mito S, Tsin A . Niclosamide induces protein ubiquitination and inhibits multiple pro-survival signaling pathways in the human glioblastoma U-87 MG cell line. PLoS One. 2017; 12(9):e0184324. PMC: 5587337. DOI: 10.1371/journal.pone.0184324. View

18.

Ween M, Oehler M, Ricciardelli C . Transforming growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer. Int J Mol Sci. 2012; 13(8):10461-10477. PMC: 3431872. DOI: 10.3390/ijms130810461. View

19.

Meazza C, Scanagatta P . Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther. 2016; 16(5):543-56. DOI: 10.1586/14737140.2016.1168697. View

20.

Guo S, Shen M, Yao H, Liu Y . Enhanced Expression of TGFBI Promotes the Proliferation and Migration of Glioma Cells. Cell Physiol Biochem. 2018; 49(3):1097-1109. DOI: 10.1159/000493293. View